Corvus Pharmaceuticals (CRVS) CEO awarded 1,000,000 share stock option

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. reported an insider equity award to its President, CEO and Director, Richard A. Miller. On 12/04/2025 he was granted a stock option to purchase 1,000,000 shares of Corvus common stock at an exercise price of $8.81 per share.

The option expires on 12/04/2035 and the underlying shares vest in equal monthly installments. Specifically, 1/36th of the shares vest each month starting on December 4, 2025, as long as he continues his service relationship with the company. Following this grant, he directly holds 1,000,000 derivative securities in the form of stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLER RICHARD A MD

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.81	12/04/2025		A		1,000,000		(1)	12/04/2035	Common Stock	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for Richard A. Miller	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corvus Pharmaceuticals (CRVS) report for Richard A. Miller?

Corvus Pharmaceuticals reported that its President, CEO and Director, Richard A. Miller, received a stock option grant on 12/04/2025 covering 1,000,000 shares of common stock.

What is the exercise price of the new Corvus Pharmaceuticals stock options?

The stock options granted to Richard A. Miller have an exercise price of $8.81 per share for the underlying Corvus Pharmaceuticals common stock.

How do the 1,000,000 Corvus Pharmaceuticals stock options vest?

The underlying shares vest and become exercisable as to 1/36th of the shares in successive, equal monthly installments starting on December 4, 2025, subject to Richard A. Miller’s continued service.

When do Richard A. Miller’s Corvus Pharmaceuticals stock options expire?

The stock options granted on 12/04/2025 are scheduled to expire on 12/04/2035, giving a ten-year term from the grant date.

How many Corvus Pharmaceuticals derivative securities does Richard A. Miller hold after this grant?

After the reported transaction, Richard A. Miller beneficially owns 1,000,000 derivative securities in the form of stock options, held with direct ownership.

What role does Richard A. Miller hold at Corvus Pharmaceuticals (CRVS)?

Richard A. Miller is identified as a Director and as an Officer of Corvus Pharmaceuticals, serving as President and CEO.